DBV Technologies logo
DBVTDBV Technologies
Trade DBVT now
DBV Technologies primary media

About DBV Technologies

DBV Technologies (EPA:DBV), (NASDAQ:DBVT) is a biopharmaceutical company focused on developing and commercializing treatments for food allergies, particularly peanut allergies in children, through its innovative Viaskin technology. This epicutaneous immunotherapy (EPIT) platform leverages a patch-based approach aiming to provide a non-invasive treatment option for patients. DBV Technologies is committed to improving the lives of those suffering from food allergies by advancing research and striving towards the commercial availability of their treatments. Operating with a strong commitment to safety, efficacy, and patient accessibility, their primary objective is to bring transformative therapies to the market, addressing a significant unmet need within the allergy therapeutic space.

What is DBVT known for?

Snapshot

Public US
Ownership
2002
Year founded
105
Employees
Bagneux, France
Head office
1 of 4
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...

Operations

All Locations
Republic of France

Produtos e/ou serviços de DBV Technologies

  • Viaskin Patch, a novel immunotherapy platform aimed at treating food allergies through epicutaneous delivery.
  • Viaskin Peanut, designed for children aged 4-11 with peanut allergies, seeking FDA approval.
  • Product pipeline includes Viaskin Milk for milk allergy treatment and Viaskin Egg for egg allergy, both in early development stages.
  • Collaborations with academic and industry partners to explore Viaskin's platform for other allergies.
  • Research and development in novel diagnostic tools for food allergies.
  • Expanding applications of the Viaskin platform to address other immune-related disorders beyond allergies.

equipe executiva do DBV Technologies

  • Mr. Daniel TasséCEO & Director
  • Ms. Virginie Simone Jeanine Verrechia Boucinha M.B.A.Chief Financial Officer
  • Dr. Pharis Mohideen M.D.Chief Medical Officer
  • Dr. Kevin P. Malobisky M.S., Ph.D., R.A.C.Chief Operations Officer
  • Mr. Jonathan NeelyVP & Head of Investor Relations
  • Ms. Michele F. RobertsonChief Legal Officer
  • Mr. James BriggsChief Human Resources Officer
  • Mr. Kevin TrappChief Commercial Officer
  • Alan KerrSenior VP & Head of Global Regulatory Affairs
  • Mr. Pascal WotlingChief External Manufacturing & Supply Chain Officer

Connect with us

Disclaimer

Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relate to your unique circumstances.

Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of or reliance on the information provided directly or indirectly, by use of this platform.